Long-chain-fatty-acid—CoA ligase 4 is an enzyme that in humans is encoded by the ACSL4 gene. [5] [6] [7] The protein encoded by this gene is an isozyme of the long-chain fatty-acid-coenzyme A ligase family.

2024年12月24日 · ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) is a Protein Coding gene. Diseases associated with ACSL4 include Intellectual Developmental Disorder, X-Linked 63 and Non-Syndromic X-Linked Intellectual Disability. Among its related pathways are Fatty acid metabolism and Integration of energy metabolism.

We applied two independent approaches-a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines-to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution.

2022年7月13日 · Recently, acyl-CoA synthetase long-chain family 4 (ACSL4) is found be participated in the activation of long chain fatty acids metabolism, immune signaling transduction, and ferroptosis, which can be a promising potential target and biomarker for anticancer.

2016年11月14日 · We applied two independent approaches—a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines—to uncover acyl-CoA synthetase long-chain family member 4...

ACSL4 is an enzyme that catalyzes the formation of long-chain acyl-CoA molecules, which are important intermediates in the biosynthesis of various types of lipids. ACSL4 is found in many tissues and is particularly abundant in the brain, liver, and adipose tissue.

2022年4月22日 · IFNγ secreted by CD8 + T cells binds to IFNR, activates the JAK-STAT1-IRF1 signaling axis, and induces ACSL4 expression in tumor cells. The increase in ACSL4 expression, in combination with AA...

ACSL4 remodels the phospholipid composition of cell membranes, regulates steroidogenesis, and balances eicosanoid biosynthesis. In addition, ACSL4-mediated metabolic reprogramming and antitumor immunity have attracted much attention in cancer biology.

ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway. New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis.

2025年2月9日 · Clinical resource with information about ACSL4, Intellectual disability, X-linked 63, and available tests. There are links to practice guidelines and authoritative resources like GeneReviews, PubMed, MedlinePlus, PharmGKB and clinicaltrials.gov.